| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 25021-0255-50 | 25021-0255 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Feb 1, 2024 | In Use | |
| 00310-1350-30 | 00310-1350 | Osimertinib | Tagrisso | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Nov 13, 2015 | In Use | |
| 83858-0105-30 | 83858-0105 | Dasatinib | PHYRAGO | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug 1, 2024 | In Use | |
| 00078-0673-01 | 00078-0673 | Topotecan | Hycamtin | 1.0 mg/1 | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Oral | Feb 24, 2017 | Dec 31, 2025 | No Longer Used |
| 75907-0363-01 | 75907-0363 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Jun 27, 2025 | In Use | |
| 25021-0230-05 | 25021-0230 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Aug 15, 2014 | Aug 31, 2026 | In Use |
| 00003-4040-60 | 00003-4040 | Repotrectinib | Augtyro | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ROS1, TRKA, TRKB, TRKC | Oral | Dec 5, 2023 | In Use | |
| 00143-9202-01 | 00143-9202 | Epirubicin Hydrochloride | Epirubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Aug 7, 2007 | In Use | |
| 00245-0823-04 | 00245-0823 | Everolimus | TORPENZ | 5.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Oct 21, 2025 | In Use | |
| 83831-0132-01 | 83831-0132 | Pemetrexed | AXTLE | 500.0 mg/20mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Jan 1, 2025 | In Use | |
| 25021-0254-16 | 25021-0254 | Docetaxel Anhydrous | Docetaxel | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug 1, 2023 | In Use | |
| 83831-0141-08 | 83831-0141 | CARBOplatin | KYXATA | 80.0 mg/8mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Sep 10, 2025 | In Use | |
| 59651-0547-30 | 59651-0547 | DASATINIB | DASATINIB | 140.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Apr 22, 2025 | In Use | |
| 43598-0045-63 | 43598-0045 | SUNITINIB MALATE | SUNITINIB MALATE | 12.5 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Nov 30, 2022 | In Use | |
| 67184-0532-02 | 67184-0532 | Imatinib mesylate | Imatinib mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jun 21, 2022 | In Use | |
| 83831-0121-04 | 83831-0121 | Cyclophosphamide | Frindovyx | 2.0 g/4mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Mar 19, 2025 | In Use | |
| 83831-0123-01 | 83831-0123 | Gemcitabine | AVGEMSI | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Aug 3, 2025 | In Use | |
| 59923-0704-14 | 59923-0704 | temozolomide | TEMOZOLOMIDE | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jan 25, 2019 | In Use | |
| 83831-0131-01 | 83831-0131 | Pemetrexed | AXTLE | 100.0 mg/4mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Jan 1, 2025 | In Use | |
| 83858-0103-60 | 83858-0103 | Dasatinib | PHYRAGO | 70.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug 1, 2024 | In Use | |
| 83831-0111-01 | 83831-0111 | Pemetrexed dipotassium | PEMETREXED DIPOTASSIUM | 100.0 mg/4mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Jan 1, 2025 | In Use | |
| 62332-0689-30 | 62332-0689 | DASATINIB | DASATINIB | 140.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Nov 11, 2025 | In Use | |
| 83831-0117-02 | 83831-0117 | Cyclophosphamide | Cyclophosphamide | 1.0 g/2mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Aug 1, 2024 | In Use | |
| 55150-0431-01 | 55150-0431 | DACTINOMYCIN | DACTINOMYCIN | 0.5 mg/mL | Chemotherapy | Antitumor Antibiotic | Carboxylic Acids and Amino Acids/Peptides | Intravenous | Mar 15, 2021 | In Use | |
| 83831-0119-01 | 83831-0119 | Cyclophosphamide | Frindovyx | 500.0 mg/mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Mar 19, 2025 | In Use |
Found 12250 results — Export these results
Home